GuardianMed j.d.o.o. Research and development in medicine   Report issue

For profit Phase 3
Founded: Zagreb Croatia (Hrvatska) (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2016
NCT02697162
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

octenidine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Catheter-Related Infections (Phase 3)

Infections (Phase 3)

Urinary Bladder, Neurogenic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1